TerminatedPhase 2NCT00267527
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
ConjuChem120 participantsDec 2005 to Sept 2006
Obesity · HIV Infections
Compare peptides
Compare two to four peptides side by side. Counts are exact.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog CJC-1295 (with DAC) | Conjugate Somapacitan | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Conjugate | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 43 | 320 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 2 (2 in people) | 83 (83 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 1 | 21 · 8 active | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | CJC-1295 (with DAC) | Somapacitan |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 2716101 | 7874 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Sogroya says: “Replacement of endogenous GH in adults with GHD”
| Adverse eventsWhole body | 11 | 7575 |
|---|
| PharmacokineticsPharmacology | 7151 | 382216 |
|---|
| Body weightMetabolic and weight | 44 | 14122 |
|---|
| Patterns of useWhole body | 22 | 66 |
|---|
| Receptor activity and mechanismPharmacology | 11 | 918 |
|---|
| Bone and jointMusculoskeletal | 11 | 22 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
CJC-1295 (with DAC) differs from Somatorelin, human GHRH(1-44) at 5 positions.
What is different
Somapacitan differs from Human growth hormone at 1 position.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | CJC-1295 (with DAC) | Somapacitan |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in cm/y | No comparable result 3 randomized-trial results measure it in another way or another unit. | 11.2 cm/y Height velocity Dose studied: 0.16 mg/kg/wk52 weeksn = 2002022 |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in d | 5.8 to 8.1 d Half-life · CJC-1295 28 d and 49 d trialsn not reported2006 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in gr/cm2 | No randomized trial result 1 result from other study designs. | −0.036 gr/cm2 Estimated difference 24 weeksn = 292025 |
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in cm² | No randomized trial result 4 results from other study designs. | −1.74 cm² Estimated treatment difference · somapacitan minus daily GH at week 52 52 weeksn not reported2020 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in per 100 patient-years | No comparable result 1 randomized-trial result measure it in another way or another unit. | 312.7 per 100 patient-years Adverse event rate 52 weeksn = 622020 |
No comparable result
3 randomized-trial results measure it in another way or another unit.
11.2 cm/y
Height velocity
Dose studied: 0.16 mg/kg/wk52 weeksn = 2002022
5.8 to 8.1 d
Half-life · CJC-1295
28 d and 49 d trialsn not reported2006
No comparable result
2 randomized-trial results measure it in another way or another unit.
No randomized trial result
1 result from other study designs.
−0.036 gr/cm2
Estimated difference
24 weeksn = 292025
No randomized trial result
4 results from other study designs.
−1.74 cm²
Estimated treatment difference · somapacitan minus daily GH at week 52
52 weeksn not reported2020
No comparable result
1 randomized-trial result measure it in another way or another unit.
312.7 per 100 patient-years
Adverse event rate
52 weeksn = 622020
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)
ConjuChem120 participantsDec 2005 to Sept 2006
Obesity · HIV Infections
Top 3 of 21 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S301 participants31 Oct 2014 to 7 May 2018
Growth Hormone Disorder · Adult Growth Hormone Deficiency
Novo Nordisk A/S200 participants20 May 2019 to 30 Sept 2025
Growth Hormone Deficiency in Children
Novo Nordisk A/S110 participants22 Jul 2021 to 18 Dec 2023
Growth Hormone Deficiency in Children